Share this article on:

New Form, New Indication for Glycopyrrolate

Aschenbrenner, Diane S. MS, APRN-BC

AJN, American Journal of Nursing: November 2010 - Volume 110 - Issue 11 - p 24
doi: 10.1097/01.NAJ.0000390516.38146.b7
Drug Watch

* Glycopyrrolate has been approved in liquid form to treat drooling secondary to neurologic problems in children three to 16 years of age.

* Its adverse effects are similar to those of all anticholinergic drugs: dry mouth, constipation, flushing, and urinary retention.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

Glycopyrrolate, an anticholinergic drug that decreases gastric and oral secretions, is now available as an oral liquid (marketed under the name Cuvposa) for treating chronic drooling in children with neurologic disorders. Glycopyrrolate (under the trade name Robinul and for either oral or parenteral administration) has historically been used as an adjunct treatment for peptic ulcer disease and to prevent drooling in patients undergoing anesthesia. Glycopyrrolate has also been used off label for years (oral tablets were crushed) to control drooling related to neurologic problems in children. The new oral liquid form is approved for use in children ages three to 16 years. Its adverse effects are similar to those of all anticholinergics: dry mouth, constipation, flushing, and urinary retention. Nurses should teach parents how to safely administer the drug and provide information on the common adverse effects. For more information, see the Food and Drug Administration's news release on the approval of the liquid form of glycopyrrolate: http://bit.ly/aVUFbK.

© 2010 Lippincott Williams & Wilkins, Inc.